Processa Pharmaceuticals Inc logo

Processa Pharmaceuticals Inc

NAS:PCSA (USA)  
$ 0.87 +0.0338 (+4.04%) 11:08 PM EST
At Loss
P/B:
0.76
Enterprise V:
$ 51.00K
Volume:
39.57K
Avg Vol (2M):
461.94K
Trade In:
Volume:
39.57K
At Loss
Avg Vol (2M):
461.94K

Business Description

Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Name Current Vs Industry Vs History
Cash-To-Debt 29.8
Equity-to-Asset 0.75
Debt-to-Equity 0.03
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.37
9-Day RSI 34.36
14-Day RSI 37.92
6-1 Month Momentum % -56.34
12-1 Month Momentum % -90.43

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.97
Quick Ratio 3.97
Cash Ratio 2.37

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.9
Shareholder Yield % -250.38

Financials (Next Earnings Date:2025-01-30 Est.)

PCSA's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PCSA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Processa Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -4.82
Beta 1
Volatility % 102.45
14-Day RSI 37.92
14-Day ATR ($) 0.115396
20-Day SMA ($) 1.052855
12-1 Month Momentum % -90.43
52-Week Range ($) 0.812 - 9.28
Shares Outstanding (Mil) 3.27

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Processa Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Processa Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Processa Pharmaceuticals Inc Frequently Asked Questions

What is Processa Pharmaceuticals Inc(PCSA)'s stock price today?
The current price of PCSA is $0.87. The 52 week high of PCSA is $9.28 and 52 week low is $0.81.
When is next earnings date of Processa Pharmaceuticals Inc(PCSA)?
The next earnings date of Processa Pharmaceuticals Inc(PCSA) is 2025-01-30 Est..
Does Processa Pharmaceuticals Inc(PCSA) pay dividends? If so, how much?
Processa Pharmaceuticals Inc(PCSA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1